-
1
-
-
0037118912
-
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine
-
CNA3002 International Study Team
-
Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M, CNA3002 International Study Team 2002. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 16: 1686-1689.
-
(2002)
AIDS
, vol.16
, pp. 1686-1689
-
-
Ait-Khaled, M.1
Stone, C.2
Amphlett, G.3
Clotet, B.4
Staszewski, S.5
Katlama, C.6
Tisdale, M.7
-
2
-
-
63149156274
-
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors
-
Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H 2009. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J Virol 83: 3059-3068.
-
(2009)
J Virol
, vol.83
, pp. 3059-3068
-
-
Aoki, M.1
Venzon, D.J.2
Koh, Y.3
Aoki-Ogata, H.4
Miyakawa, T.5
Yoshimura, K.6
Maeda, K.7
Mitsuya, H.8
-
3
-
-
1442355578
-
HIV drug resistance
-
Clavel F, Hance AJ 2004. HIV drug resistance. N Engl J Med 350: 1023-1035.
-
(2004)
N Engl J Med
, vol.350
, pp. 1023-1035
-
-
Clavel, F.1
Hance, A.J.2
-
4
-
-
0035870551
-
A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfi-navir or saquinavir
-
Eron JJ, Haubrich R, Lang W, Pagano G, Millard J, Wolfram J, Snowden W, Pedneault L, Tisdale M 2001. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfi-navir or saquinavir. J Acquir Immune Defic Syndr 26: 458-461.
-
(2001)
J Acquir Immune Defic Syndr
, vol.26
, pp. 458-461
-
-
Eron, J.J.1
Haubrich, R.2
Lang, W.3
Pagano, G.4
Millard, J.5
Wolfram, J.6
Snowden, W.7
Pedneault, L.8
Tisdale, M.9
-
5
-
-
34748818983
-
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments
-
Spanish Group for the Study of Antiretroviral Drug Resistance
-
Garriga C, Pérez-Elías MJ, Delgado R, Ruiz L, Nájera R, Pumarola T, Alonso-Socas M, del M, García-Bujalance S, Menéndez-Arias L, Spanish Group for the Study of Antiretroviral Drug Resistance 2007. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol 79: 1617-1628.
-
(2007)
J Med Virol
, vol.79
, pp. 1617-1628
-
-
Garriga, C.1
Pérez-Elías, M.J.2
Delgado, R.3
Ruiz, L.4
Nájera, R.5
Pumarola, T.6
Alonso-Socas, M.7
Del, M.8
García-Bujalance, S.9
Menéndez-Arias, L.10
-
6
-
-
33750253231
-
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004
-
Hemelaar J, Gouws E, Ghys PD, Osmanov S 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13-W23.
-
(2006)
AIDS
, vol.20
-
-
Hemelaar, J.1
Gouws, E.2
Ghys, P.D.3
Osmanov, S.4
-
7
-
-
0344474694
-
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse tran-scriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
-
Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwen-berge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse tran-scriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimi-crob Agents Chemother 42: 269-276.
-
(1998)
Antimi-crob Agents Chemother
, vol.42
, pp. 269-276
-
-
Hertogs, K.1
de Béthune, M.P.2
Miller, V.3
Ivens, T.4
Schel, P.5
Van Cauwen-berge, A.6
Van Den Eynde, C.7
van Gerwen, V.8
Azijn, H.9
van Houtte, M.10
Peeters, F.11
Staszewski, S.12
Conant, M.13
Bloor, S.14
Kemp, S.15
Larder, B.16
Pauwels, R.17
-
8
-
-
79951702447
-
Brazilian Network for HIV Drug Resistance Surveillance: A survey of individuals recently diagnosed with HIV
-
Inocencio LA, Pereira AA, Sucupira MC, Fernandez JC, Jorge CP, Souza DF, Fink HT, Diaz RS, Becker IM, Suffert TA, Arruda MB, Macedo O, Simão MB, Tanuri A 2009. Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc 12: 20.
-
(2009)
J Int AIDS Soc
, vol.12
, pp. 20
-
-
Inocencio, L.A.1
Pereira, A.A.2
Sucupira, M.C.3
Fernandez, J.C.4
Jorge, C.P.5
Souza, D.F.6
Fink, H.T.7
Diaz, R.S.8
Becker, I.M.9
Suffert, T.A.10
Arruda, M.B.11
Macedo, O.12
Simão, M.B.13
Tanuri, A.14
-
9
-
-
77949324191
-
Update of the drug resistance mutations in HIV-1: December 2009
-
Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 17: 138-145.
-
(2009)
Top HIV Med
, vol.17
, pp. 138-145
-
-
Johnson, V.A.1
Brun-Vezinet, F.2
Clotet, B.3
Gunthard, H.F.4
Kuritzkes, D.R.5
Pillay, D.6
Schapiro, J.M.7
Richman, D.D.8
-
10
-
-
0028085161
-
Recombinant virus assay: A rapid, phe-notypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
-
Kellam P, Larder BA 1994. Recombinant virus assay: a rapid, phe-notypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 38: 23-30.
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 23-30
-
-
Kellam, P.1
Larder, B.A.2
-
11
-
-
0242659106
-
Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation
-
Lam E, Parkin NT 2003. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Clin Infect Dis 37: 1273-1274.
-
(2003)
Clin Infect Dis
, vol.37
, pp. 1273-1274
-
-
Lam, E.1
Parkin, N.T.2
-
12
-
-
0029028067
-
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
-
Larder BA, Kemp SD, Harrigan PR 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
-
(1995)
Science
, vol.269
, pp. 696-699
-
-
Larder, B.A.1
Kemp, S.D.2
Harrigan, P.R.3
-
13
-
-
33846243843
-
N88D facilitates the co-occurrence of D30N and L90M and the development of multi-drug resistance in HIV type 1 protease following nelfinavir treatment failure
-
Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW 2006. N88D facilitates the co-occurrence of D30N and L90M and the development of multi-drug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses 22: 1300-1305.
-
(2006)
AIDS Res Hum Retroviruses
, vol.22
, pp. 1300-1305
-
-
Mitsuya, Y.1
Winters, M.A.2
Fessel, W.J.3
Rhee, S.Y.4
Hurley, L.5
Horberg, M.6
Schiffer, C.A.7
Zolopa, A.R.8
Shafer, R.W.9
-
14
-
-
0035663666
-
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy
-
Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Mas-sip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V 2001. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antivir Ther 6: 179-183.
-
(2001)
Antivir Ther
, vol.6
, pp. 179-183
-
-
Mouroux, M.1
Descamps, D.2
Izopet, J.3
Yvon, A.4
Delaugerre, C.5
Matheron, S.6
Coutellier, A.7
Valantin, M.A.8
Bonmarchand, M.9
Agut, H.10
Mas-Sip, P.11
Costagliola, D.12
Katlama, C.13
Brun-Vezinet, F.14
Calvez, V.15
-
15
-
-
0031692748
-
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
-
Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR, Markowitz M 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 42: 2637-2644.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 2637-2644
-
-
Patick, A.K.1
Duran, M.2
Cao, Y.3
Shugarts, D.4
Keller, M.R.5
Mazabel, E.6
Knowles, M.7
Chapman, S.8
Kuritzkes, D.R.9
Markowitz, M.10
-
16
-
-
3342913702
-
Distribution of human immunodeficiency virus type 1 protease and reverse tran-scriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing
-
Rhee SY, Liu T, Ravela J, Gonzales MJ, Shafer RW 2004. Distribution of human immunodeficiency virus type 1 protease and reverse tran-scriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 48: 3122-3126.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 3122-3126
-
-
Rhee, S.Y.1
Liu, T.2
Ravela, J.3
Gonzales, M.J.4
Shafer, R.W.5
-
17
-
-
33751235598
-
Genotypic predictors of human immunodeficiency virus type 1 drug resistance
-
Rhee SY, Taylor J, Wadhera G, Ben-Hur A, Brutlag DL, Shafer RW 2006. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA 103: 17355-17360.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 17355-17360
-
-
Rhee, S.Y.1
Taylor, J.2
Wadhera, G.3
Ben-Hur, A.4
Brutlag, D.L.5
Shafer, R.W.6
-
18
-
-
0141631851
-
Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART
-
Røge BT, Katzenstein TL, Nielsen HL, Gerstoft J 2003. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Med 4: 38-47.
-
(2003)
HIV Med
, vol.4
, pp. 38-47
-
-
Røge, B.T.1
Katzenstein, T.L.2
Nielsen, H.L.3
Gerstoft, J.4
-
19
-
-
0033965761
-
Human immunodeficiency virus reverse transcriptase and protease sequence database
-
Shafer RW, Jung DR, Betts BJ, Xi Y, Gonzales MJ 2000. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 28: 346-348.
-
(2000)
Nucleic Acids Res
, vol.28
, pp. 346-348
-
-
Shafer, R.W.1
Jung, D.R.2
Betts, B.J.3
Xi, Y.4
Gonzales, M.J.5
-
20
-
-
70349274463
-
Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil
-
Sprinz E, Netto EM, Patelli M, Lima JS, Furtado JJ, da Eira M, Zajdenverg R, Madruga JV, Lewi DS, Machado AA, Pedro RJ, Soares MA 2009. Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS Res Hum Re-troviruses 25: 861-867.
-
(2009)
AIDS Res Hum Re-troviruses
, vol.25
, pp. 861-867
-
-
Sprinz, E.1
Netto, E.M.2
Patelli, M.3
Lima, J.S.4
Furtado, J.J.5
da Eira, M.6
Zajdenverg, R.7
Madruga, J.V.8
Lewi, D.S.9
Machado, A.A.10
Pedro, R.J.11
Soares, M.A.12
-
21
-
-
0036168452
-
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1
-
Sugiura W, Matsuda Z, Yokomaku Y, Hertogs K, Larder B, Oishi T, Okano A, Shiino T, Tatsumi M, Matsuda M, Abumi H, Takata N, Shirahata S, Yamada K, Yoshikura H, Nagai Y 2002. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 46: 708-715.
-
(2002)
Antimicrob Agents Chemother
, vol.46
, pp. 708-715
-
-
Sugiura, W.1
Matsuda, Z.2
Yokomaku, Y.3
Hertogs, K.4
Larder, B.5
Oishi, T.6
Okano, A.7
Shiino, T.8
Tatsumi, M.9
Matsuda, M.10
Abumi, H.11
Takata, N.12
Shirahata, S.13
Yamada, K.14
Yoshikura, H.15
Nagai, Y.16
-
22
-
-
0034002883
-
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
-
Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT 2000. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 74: 4414-4419.
-
(2000)
J Virol
, vol.74
, pp. 4414-4419
-
-
Ziermann, R.1
Limoli, K.2
Das, K.3
Arnold, E.4
Petropoulos, C.J.5
Parkin, N.T.6
|